Union Bancaire Privee UBP SA Sells 56,036 Shares of Pfizer Inc. $PFE

Key Points

• Union Bancaire Privee UBP SA reduced its stake in Pfizer Inc. by 30.1% during the second quarter, selling 56,036 shares, bringing its total holdings to 129,946 shares valued at $3.15 million.
• Institutional investors currently own approximately 68.36% of Pfizer's stock, with several firms like Pacer Advisors and Amundi significantly increasing their positions during the first quarter.
• Pfizer reported a quarterly EPS of $0.78, exceeding expectations, and has set its FY 2025 guidance at 2.900-3.100 EPS as analysts forecast an EPS of 2.95 for the current year.

Union Bancaire Privee UBP SA lessened its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 30.1% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 129,946 shares of the biopharmaceutical company's stock after selling 56,036 shares during the quarter. Union Bancaire Privee UBP SA's holdings in Pfizer were worth $3,150,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of PFE. Pacer Advisors Inc. increased its stake in Pfizer by 856.8% in the first quarter. Pacer Advisors Inc. now owns 20,053,828 shares of the biopharmaceutical company's stock valued at $508,164,000 after purchasing an additional 17,957,928 shares in the last quarter. Amundi grew its holdings in shares of Pfizer by 43.4% in the 1st quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company's stock valued at $1,265,277,000 after acquiring an additional 15,758,846 shares in the last quarter. Nuveen LLC bought a new stake in shares of Pfizer during the 1st quarter worth approximately $389,861,000. Goldman Sachs Group Inc. grew its stake in shares of Pfizer by 51.9% in the first quarter. Goldman Sachs Group Inc. now owns 26,456,457 shares of the biopharmaceutical company's stock valued at $670,407,000 after buying an additional 9,041,990 shares in the last quarter. Finally, Assenagon Asset Management S.A. increased its stake in shares of Pfizer by 307.5% during the 1st quarter. Assenagon Asset Management S.A. now owns 10,046,340 shares of the biopharmaceutical company's stock worth $254,574,000 after purchasing an additional 7,581,030 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on PFE. Bank of America boosted their price objective on Pfizer from $27.00 to $28.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Morgan Stanley lifted their price objective on shares of Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a research note on Wednesday, August 6th. Wall Street Zen cut shares of Pfizer from a "buy" rating to a "hold" rating in a report on Sunday. Finally, Citigroup upped their target price on Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $28.12.

Pfizer Stock Up 0.3%

Shares of Pfizer stock opened at $23.84 on Tuesday. The company has a market cap of $135.54 billion, a P/E ratio of 12.68, a PEG ratio of 0.77 and a beta of 0.55. Pfizer Inc. has a one year low of $20.92 and a one year high of $30.43. The firm has a fifty day moving average of $24.54 and a two-hundred day moving average of $24.11. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. The company had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company's quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.